Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
12
×
clinical trials
12
×
life sciences
national blog main
biotech
boston blog main
national top stories
new york blog main
new york top stories
boston top stories
san francisco blog main
san francisco top stories
fda
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
alnylam pharmaceuticals
drugs
eli lilly
inclisiran
new york
regeneron pharmaceuticals
san diego blog main
san diego top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
detroit blog main
detroit top stories
migraine research foundation
What
drug
12
×
medicines
new
fda
approval
cholesterol
medco
migraine
won
class
decades
developed
lowering
pricing
amgen
announced
big
bio
brings
cancer
data
eli
heart
lilly
market
medicine
nod
pain
roundup
starts
twice
year
aces
acquire
acute
addresses
advanced
advantages
agreed
alnylam
Language
unset
Current search:
drug
×
amgen
×
" clinical trials "
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines